PUNE, India, October 2, 2015 /PRNewswire/ --
Market research reports titled Hyperalgesia - Pipeline Review, H2 2015 and Hyperalgesia Global Clinical Trials Review, H1, 2015 are now available in the pharmaceuticals business intelligence collection of RnRMarketResearch.com.
Complete report on hyperalgesia pipeline review spread across 36 pages, talking about 2 companies, 6 drug profiles and supported with 16 tables and 13 figures is now available at http://www.rnrmarketresearch.com/hyperalgesia-pipeline-review-h2-2015-market-report.html .
The Hyperalgesia - Pipeline Review, H2 2015 market research report provides an overview of the Hyperalgesia's therapeutic pipeline and comprehensive information on comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperalgesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Cara Therapeutics, Inc. and Shionogi & Co., Ltd. are companies involved in hyperalgesia therapeutics development and mentioned in this research. Drug profiles covered in the report include AX-007, BAM-822, CR-701, GERPOOI, ketoprofen, LASSBio-873, Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS and Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia. The report provides a snapshot of the global therapeutic landscape of Hyperalgesia. It reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The research covers key players involved in the therapeutics development for Hyperalgesia and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Hyperalgesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is covered along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Hyperalgesia pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products are also provided in this research on Hyperalgesia - Pipeline Review, H2 2015 available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=419692 .
The second research titled Hyperalgesia Global Clinical Trials Review, H1, 2015 provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Hyperalgesia clinical trial overview of companies like Pfizer Inc., GlaxoSmithKline plc, Air Liquide S.A., Raptor Pharmaceuticals Corp., Pharmed Holding GmbH, PainCeptor Pharma Corporation, IBSA Institut Biochimique SA, H. Lundbeck A/S, AstraZeneca PLC as well as government organizations and institutes like Medical University of Vienna, Rigshospitalet, Massachusetts General Hospital, University Hospital, Bordeaux, Yonsei University, National Institute of Dental and Craniofacial Research, Johns Hopkins University, University of Washington, University of Zurich and Seoul National University Hospital are covered in this research spread across 69 pages and available at http://www.rnrmarketresearch.com/hyperalgesia-global-clinical-trials-review-h1-2015-market-report.html .
Explore more reports on pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research